anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Students enrolled in the MetroHealth School Health Program (signed parental consent on file in electronic health record) and have a diagnosis of asthma on active problem list, or were seen in Emergency Department or Express Care in past 12 months for asthma related diagnosis, or have a rescue or controller inhaled medication on current medication list, will be considered for inclusion. Research staff will call families who meet inclusion criteria to discuss the study, determine interest in inclusion and obtain consent. Once enrolled baseline measures will be obtained, including level of asthma control and responses on the Environmental Screening Tool (EST) and the Community Advocacy Program Home Asthma Screening Tool (CAPHAST) (see CREST phone screening tool). Participants will then be randomized into two groups. The first group will receive regular care. The second group will receive the Asthma Home Assessment Intervention. Based on results of the screening tool and home assessments, participants will be placed into one of four groups (see CREST study design): GROUP A (no referral) GROUP B (home assessment only) GROUP C (home assessment and remediation) and GROUP D (medical legal partnership referral only) Participants randomized to regular care will be assessed for outcome measures at 3 and 6 months after randomization. Those randomized to the intervention arm will be assessed at 3 and 6 months after completion of intervention.
OBJECTIVES: Cranial nerve (CN) involvement is not a common feature of typical chronic inflammatory demyelinating polyneuropathy (CIDP). Patients with acute presentation of CN palsy in CIDP may be misdiagnosed and treated as other pathologies.
METHODS: We report a patient with multiple cranial neuropathies at the onset of CIDP in detail. In addition, we reviewed a large cohort of patients with CN involvement in CIDP and summarized their characteristics and clinical findings.
RESULTS: We presented a 28-year-old woman who presented with progressive weakness and involvement of CN III, VII, X, XII in the subacute phase who was diagnosed as CIDP and was treated accordingly. A scoping review of the literature resulted in a total of 59 patients with available patient-level data [61.2% men, median age of 32 (Q1-Q3; 20-51.5) years]. CN impairment was present in the acute phase of the polyneuropathy in 10 out of 43 patients (23.3%), while it took a median of 7.7 [Q1-Q3; 3-13] years for other patients to present CN palsy. Sensitivity analysis did not reveal any difference among patients with acute-phase presentation of CN symptoms (N = 11) compared with those with delayed CN palsy (N = 33) in terms of demographics, patterns of CN involvement, associated diminished sensorimotor findings, or relapse. However, patients with acute presentation of CN palsy underwent plasmapheresis approximately 4 times more than those with delayed CN presentations (45.5% vs. 12.1%, P = 0.02).
CONCLUSION: In this case presentation and review study, we observed that in one-fourth of patients with CIDP and CN neuropathy, CN involvement occurred in the acute phase. This finding indicates the necessity of considering CIDP among differential diagnoses of patients with CN involvement and polyneuropathies.
FIELD: medicine, hepatology, virology, pharmacy. SUBSTANCE: invention can be used for treatment and prophylaxis of viral hepatitis. Invention proposes an agent comprising complex of cationic liposome with double-stranded poly(I) x poly(C) with chain length from 100 to 500 nucleotide pairs and an agent containing complex of medicinal carrier also including as obligatory components, for example, 2-O-(2-diethylaminoethyl)carbamoyl-1,3-O-dioleylglycerol and phospholipid with poly(I) x poly(C) with mean chain length from 100 to 500 nucleotide pairs. Invention provides the development of a new agent used for prophylaxis and treatment of viral hepatitis. EFFECT: valuable medicinal properties of agents. 4 cl, 1 tbl, 2 dwg, 14 ex
To provide Bouxcuengh pharmaceutical compositions for supplementing and regulating spirit, and to provide methods for producing the same.SOLUTION: The present invention discloses a Bouxcuengh pharmaceutical composition for supplementing and regulating spirit, which is prepared using raw materials of 10 to 60 pts.wt. of Gosinhvahenj, 10 to 50 pts.wt. of Raethozduzlingz, 10 to 40 pts.wt. of yazgyanghgez, 10 to 30 pts.wt. of Gaekdinbit, 5 to 20 pts.wt. of Naengigveq, 10 to 25 pts.wt. of Ganoderma, 10 to 25 pts.wt. of Sagieng, and 10 to 30 pts.wt. of Gitgwngq, and also a method for producing the same is provided. Advantageous effects of the present invention are as follows. The present invention provides a Bouxcuengh pharmaceutical composition for supplementing and regulating spirit, which has clear effects of adjusting the flow of spirit to improve the state of emptiness, and of preparing Long Lu and Huo Lu, and which improves symptoms, such as mental illness, wasted spirit, mental and physical fatigue, low spirit and tedious, and low voice and faint breath, better, as well as also provides a method for preparing the same, which is easy to operate, and can exert the crude drug efficacy sufficiently.SELECTED DRAWING: None
The control group includes hospital consultations (usual care) on the hospital 2-3 times a week (1-2 hours) and the possibility to call the neonatal ward 24 hours a day all week until the infant gets full nutrition from the breast or bottle and gains weight. The parents register nutrition on a paper between the visits to the hospital.
Calcium acetate tablet acts as a phosphate binder. Its chemical name is calcium acetate. Its molecular formula is C4H6CaO4, and its molecular weight is 158.17. Its structural formula is:

Each calcium acetate tablet contains 667 mg of calcium acetate, (anhydrous; Ca (CH3COO)2; MW = 158.17 grams) equal to 169 mg (8.45 mEq) calcium. In addition, each tablet contains following inactive ingredients: crospovidone, magnesium stearate and sodium lauryl sulfate. Calcium acetate tablets are administered orally for the control of hyperphosphatemia in end stage renal failure.
PURPOSE:To make a slightly soluble drug into ultrafine particles and to improve and promote absorption of slightly soluble drug in digestive tube by blending a low-molecular saccharide with the slightly soluble drug and grinding. CONSTITUTION:A mixture of a slightly soluble drug and a saccharide (e.g. glucose) or a sugaralcohol is ground by high-speed stirring or impact grinding and the slightly soluble drug is made into ultrafine particles having <=1 micron. 1 pts.wt. of the main drug is used with 1-50 pts.wt. saccharide. The slightly soluble drug has <=5mg/ml water solubility at 20 deg.C and has insufficient absorption when made into solid preparation by conventional pharmaceutical manufacturing. The drug is nifedipine, indomethacin, cortisone, etc. The ultrafine particles of the drug is contained as an active ingredient and can be pharmaceutically manufactured.
Epilepsy is one of the most common neurological diseases worldwide. Anti-seizure medications (ASMs) with anticonvulsants remain the mainstay of epilepsy treatment. Currently used ASMs are, however, ineffective to suppress seizures in about one third of all patients. Moreover, ASMs show no significant impact on the pathogenic mechanisms involved in epilepsy development or disease progression and may cause serious side-effects, highlighting the need for the identification of new drug targets for a more causal therapy. Compelling evidence has demonstrated a role for purinergic signalling, including the nucleotide adenosine 5'-triphosphate (ATP) during the generation of seizures and epilepsy. Consequently, drugs targeting specific ATP-gated purinergic receptors have been suggested as promising treatment options for epilepsy including the cationic P2X7 receptor (P27XR). P2X7R protein levels have been shown to be increased in the brain of experimental models of epilepsy and in the resected brain tissue of patients with epilepsy. Animal studies have provided evidence that P2X7R blocking can reduce the severity of acute seizures and the epileptic phenotype. The current review will provide a brief summary of recent key findings on P2X7R signalling during seizures and epilepsy focusing on the potential clinical use of treatments based on the P2X7R as an adjunctive therapeutic strategy for drug-refractory seizures and epilepsy.
There is considerable controversy on the role of physical activity in irritable bowel disease (IBD) since published reports are conflicting. It is well known that there is known relapse with specific treatment in IBD. This, in addition to onset of extraintestinal symptoms creates a need to think of alternate approaches. In this context, the current article describes the need of a multi-institutional study with standard protocol of physical activity for documenting its effect on both the primary disease and the extra alimentary manifestations. This paper also points out the possibility of using adjuvant complementary medicine such as yoga, whose effects have been documented in other diseases like irritable bowel syndrome. A third approach could be to focus on the intestinal dysbiosis in IBD and concentrate on research on restoring the microbial flora to normal, to see whether the extra-intestinal symptoms are alleviated.
Nerve blockade administration will be carried out per standard of care. All patients will receive single injection under ultrasound guidance with adductor canal block comprised of 20 ml 0.25% plain bupivacaine + 10 ml LB (133 mg) with the total volume of 30 ml; 10 ml 0.25% plain bupivacaine + 10 ml LB (133 mg) with the total volume of 20 ml will be administered through an Interspace between the popliteal artery and capsule of the posterior knee (iPACK) block.
BACKGROUND: There has been a recent decrease in the prevalence of infectious diseases in children worldwide due to the usage of vaccines. However, the association between cesarean delivery and infectious diseases remains unclear. Here, we aimed to clarify the association between cesarean delivery and the development of infectious diseases.
METHODS: This study is a cross-sectional study. We used data from the Japan Environment and Children's Study, which is a prospective, nationwide, government-funded birth cohort study. The data of 104,065 records were included. Information about the mode of delivery, central nervous system infection (CNSI), otitis media (OM), upper respiratory tract infection (URTI), lower respiratory tract infection (LRTI), gastrointestinal infection (GI), and urinary tract infection (UTI) was obtained from questionnaires and medical records transcripts. Multiple logistic regression analysis was used to assess the association between cesarean delivery and CNSI, OM, URTI, LRTI, GI, and UTI risk.
RESULTS: We included a total of 74,477 subjects in this study, of which 18.4% underwent cesarean deliveries. After adjusting for the perinatal, socioeconomic, and postnatal confounding factors, children born by cesarean delivery did not have an increased risk of developing CNSI (95% confidence interval [CI] 0.46-1.35), OM (95% CI 0.99-1.12), URTI (95% CI 0.97-1.06), LRTI (95% CI 0.98-1.15), GI (95% CI 0.98-1.11), or UTI (95% CI 0.95-1.45).
CONCLUSIONS: This nationwide cohort study did not find an association between cesarean delivery and CNSI, OM, URTI, LRTI, GI, and UTI. However, further studies are needed to evaluate the role of cesarean delivery in the development of infectious diseases.
Participants will choose one facial sunscreen (SPF 70) out of the two (one with a light tone \[Color 2.0\] and another with a medium tone \[Color 3.0\]) based on the tone that best suits their skin color. At home, they will apply a generous amount of facial sunscreen to the face twice daily and will reapply when they feel the need up to 84 + (-) 2 days.
BACKGROUND AND OBJECTIVE: Autoimmune encephalitis (AE) is often associated with clinically significant memory impairment. This study aimed to evaluate memory in a cross-sectional prospective AE cohort using multiple memory paradigms.
METHODS: 52 patients (50% seropositive) meeting Graus criteria for possible AE were prospectively recruited between October 2019 and August 202. A comprehensive examination of memory was performed, including tests of supraspan verbal memory (list learning), logicosemantic memory (story learning), figural memory (learning of geometric designs), and verbal associative learning (verbal paired associates). Memory scores were compared to demographically adjusted normative data. Pattern analysis was conducted to assist in the identification of patterns in memory performances.
RESULTS: Mean memory scores were not significantly below the normative mean. At an individual patient level, over 20% of the cohort exhibited impaired delayed figural memory, supraspan verbal memory learning and recall. Observed performances were significantly below expected performance for story learning (p = 0.017) and recall (p = 0.003), figural recall (p < 0.0001), initial acquisition (p < 0.001) and final acquisition of a list (p < 0.001) and all delayed recall measures of the list (p < 0.00001). 54.76% of patients exhibited intact psychometrics, and 16 distinct patterns of impairment emerged, indicating variability in memory outcomes.
DISCUSSION: While statistical evidence for memory impairment did not emerge at an aggregate level, a proportion of patients present with evidence of abnormal memory performance on psychometrics. Variability in impaired memory measures argues for an individualised patient-focused approach to clinical assessment in AE. Future research should validate these findings with a larger sample size and explore the relationships between memory profiles and other cognitive functions.
Continuous energy restriction is currently considered the first-line dietary therapy for weight loss in individuals with obesity. Recently, interventions which alter the eating window and time of eating occasions have been explored as means to achieve weight loss and other cardiometabolic improvements such as a reduction in blood pressure, glycaemia, lipids and inflammation. It is unknown, however, whether these changes result from unintentional energy restriction or from other mechanisms such as the alignment of nutrient intake with the internal circadian clock. Even less is known regarding the safety and efficacy of these interventions in individuals with established chronic noncommunicable disease states, such as cardiovascular disease. This review examines the effects of interventions which alter both eating window and time of eating occasions on weight and other cardiometabolic risk factors in both healthy participants and those with established cardiovascular disease. We then summarise the state of existing knowledge and explore future directions of study.
In a supine position with a cardboard blocking view of their legs, patients will have six, 0.25\*40mm sterilized stainless steel acupuncture needles (Dongbang Acupuncture, Inc., Seoul, South Korea) inserted into six acupoints (sites ST36, LV3, KI2, bilaterally) on their lower legs. After insertion, the needles will be stimulated at 2-4Hz, 10s at each point (1min total), immediately after insertion, 5min, 10min, 15min and just before removal. After which the needles will be removed.
Subjects in active treatment will be vaccinated with GL-0817 with the adjuvants Poly-ICLC (Hiltonol®) and GM-CSF (Sargramostim, Leukine®) 3 times at 3-week intervals followed by 7 doses at 3-month intervals beginning at Week 18. Patients will receive IV Cyclophosphamide 1 day prior to the first 3 vaccinations.
This is an interventional, sham controlled, double-blind study in patients with early to moderate Alzheimer's Disease (AD). The study will enroll approximately 55 individuals with amyloid positive Mild Cognitive Impairment (MCI) or AD. Each subject will undergo a 1-2 visit screening period consisting of a physical and neurological exam, medical history and medication review, safety questionnaires, and cognitive testing. Each subject will then undergo 5-7 baseline visits including neuropsychological testing (memory and thinking tests), amyloid Positron Emission Tomography (PET) imaging if one is not available or it has been greater than 6 months, tau PET imaging, tACS-EEG (transcranial alternating current stimulation and electroencephalogram) assessment, TMS-EEG (transcranial magnetic stimulation and electroencephalogram) plasticity assessment, functional magnetic resonance imaging (fMRI), blood and saliva sample collection, and optional lumbar puncture (LP). Participants will be randomly assigned to one of four groups: stimulation for 2 weeks or 4 weeks, once a day or twice a day. One of the groups is a sham group. This means that this group will not receive actual tACS. Each session will be one hour of either individualized gamma-frequency (40 Hz) tACS or sham tACS, depending on the assigned group. Subjects will be assessed for any side effects before and after each session and complete a short memory and thinking test either daily or weekly. At the end of the daily sessions, 5-7 follow up visits will include a repeat of the baseline measures including amyloid and tau PET scans. Long-term follow-up visits will include an EEG, cognitive testing and an amyloid PET scan. The PET imaging studies will be conducted at Massachusetts General Hospital and up to 5 PET scans will be performed.
BACKGROUND: Evidence shows that cancer patients are more likely to have hyperuricemia (HUA) compared to the general population, with lipid metabolism playing a significant role. However, it is still unclear whether there is a non-linear relationship between the non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio (NHHR) and HUA in these patients. This study aims to explore the association between NHHR and HUA in cancer patients.
METHODS: This study included participants from the NHANES database from 2007 to 2018. We used multivariable logistic regression, restricted cubic splines (RCS) analysis, and subgroup analysis to examine the association between NHHR and HUA and gout in cancer patients, as well as to investigate differences in this association among specific subgroups.
RESULTS: A total of 2826 participants were included, with a HUA prevalence of 24.30%. Weighted multivariable logistic regression showed that for each unit increase in NHHR, the odds of HUA in cancer patients increased by 16% (95% confidence interval [CI]: 1.06, 1.29, P = 0.002). When NHHR was divided into tertiles, those in the highest tertile (Q3) had a 1.84 times higher odds of developing HUA compared to those in the lowest tertile (Q1) (95% CI: 1.32, 2.58, P < 0.001). However, there was no significant association with gout. RCS analysis further revealed a significant non-linear positive association, particularly among males. Subgroup analysis and interaction tests indicated a stronger association in cancer patients who did not have a history of stroke.
CONCLUSION: There is a non-linear association between NHHR and HUA in cancer patients.
Will be provided with the "best recommended standard of care" based on recommendations from published studies and guidelines2,10,13,25,26 including educating on the importance and application of chronic hair removal to provide a standardized education and training to all patients in the control group. They will have the option to schedule additional in-person visits for further education and training on hair removal.
PURPOSE:A water-in-oil type cosmetic, prepared by using an emulsifying agent consisting of a 2-hydroxy-3-alkoxypropylglyceryl ether, etc., a multivalent metallic salt of a fatty acid and a specific inorganic salt in a specific proportion, containing a large amount of water stably, and having a low viscosity. CONSTITUTION:A water-in-oil type cosmetic containing an oil base for the cosmetic, an emulsifying agent and water. 2-Hydroxy-3-alkoxypropyl glyceryl ether or 2,3-dialkoxypropyl glyceryl ether of the formula (R is 10-20C saturated or unsaturated straight chain hydrocarbon group; R' is H or alkyl), a multivalent metallic salt of a 10-22C saturated or unsaturated fatty acid, e.g. aluminum monostearate, and an inorganic salt, e.g. potassium sulfate, having >=0.2g/100g water solubility in water at 20 deg.C are used as the emulsifying agent at (90.9-54)/ (0.1-20)/(9-45) ratio. Preferably, the resultant emulsifying agent is contained in an amount of 0.5-10wt% in the cosmetic.
Subjects will be administered with an oral single dose of 100 mg AK0529 or placebo. The dose group begins treatment on Day 1.
The invention discloses an oral traditional Chinese medicine liquid for treating chronic pelvic inflammation and a preparation method thereof. The oral traditional Chinese medicine liquid is prepared from the following raw materials in parts by weight: 10 to 15 parts of angelica sinensis, 20 to 30 parts of the root of red-rooted salvia, 15 to 20 parts of root of common peony, 5 to 10 parts of lychee seeds, 12 to 18 parts of rhizoma corydalis, 10 to 15 parts of broadbean flower, 14 to 22 parts of rhizoma sparganii, 8 to 12 parts of curcuma zedoary, 5 to 10 parts of aleppo avens, 18 to 24 parts of patrinia, 9 to 16 parts of sargent gloryvine, 5 to 10 parts of golden cypress, 20 to 30 parts of poria cocos, 15 to 20 parts of loosestrife, 6 to 11 parts of rhizoma cyperi, 12 to 18 parts of tsubaki root bark and 5 to 10 parts of gourd shell. The oral traditional Chinese medicine liquid has the functions of clearing heat, promoting diuresis, activating blood, dissolving stasis, regulating the flow of vital energy, removing obstruction stasis as well as relieving swelling and pain, and is stable in efficacy, good in treatment effect, short in treatment course, high in cure rate and low in recurrence rate and cannot generate toxic side effects and adverse reactions. Thus, the oral traditional Chinese medicine liquid is safe and reliable. The total effective rate of the oral traditional Chinese medicine liquid reaches more than 95% when the oral traditional Chinese medicine liquid is used for treating the chronic pelvic inflammation caused by dampness-heat and stasis. In addition, the oral traditional Chinese medicine liquid is simple to take and low in cost. Thus, the oral traditional Chinese medicine liquid is worthy of clinical popularization and application.
OBJECTIVES: The purpose of this review was to summarize what is known about criteria, assessments, and recommendations for evaluating cochlear implant (CI) candidacy in children with residual hearing.
METHODS: Peer-reviewed studies were identified through a systematic search in five electronic databases. Articles were screened and assessed for eligibility. From the eligible studies, data were extracted to summarize and present a narrative synthesis of the findings.
RESULTS: A total of seven articles (two reviews and five primary studies) were included in the final analysis. Hearing levels better than the moderately severe to severe range (65-90 dB HL) tend to be supported as audiological candidacy criteria for pediatric CI. Recommendations for candidacy consideration based on audiologic thresholds range from 65 to 80 dB Hl pure-tone average as the lower boundary. Our review did not identify any specific assessment protocols. However, additional decision-making considerations related to borderline hearing loss configurations and assessment tools (the Speech Intelligibility Index and the Pediatric Minimum Speech Test Battery) were identified. Supplementary assessment considerations were also reported.
CONCLUSION: There is limited information regarding specific assessment protocols for children with residual hearing. The literature is primarily focused on guidelines related to audiologic criteria, although it is widely recommended that other areas of functioning should also be considered. Most recommendations appear to be based on expert opinion, clinical expertise, and evidence from overall pediatric CI outcomes rather than empirical evidence targeting children with residual hearing. There is an ongoing need for research to further develop protocols and tools that can assist clinicians and families in making cochlear implantation decisions for children with residual hearing.